» Articles » PMID: 21455597

Matrix Metalloproteinase-9 is Associated with Relapse and Prognosis of Patients with Colorectal Cancer

Overview
Journal Ann Surg Oncol
Publisher Springer
Specialty Oncology
Date 2011 Apr 2
PMID 21455597
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Matrix metalloproteinase-9 is a member of the MMP family, which is overexpressed in some solid tumors and is thought to enhance tumor invasion and metastasis ability. The present study aims to examine MMP-9 expression in human colorectal cancer and to determine its association with clinicopathological characteristics and prognosis.

Methods: Colorectal cancer and adjacent normal tissues from 192 patients were investigated by immunohistochemical assay. Staining evaluation results were analyzed statistically in relation to various clinicopathological characters, disease-free survival, and overall survival.

Results: High level of MMP-9 expression was detected in colorectal cancer, significantly more than in normal colorectal epithelial cells. In colorectal cancer, MMP-9 was significantly positively correlated with depth of invasion, lymph node metastasis, and distant metastasis. However, no correlations between MMP-9 expression and patient age, sex, tumor location or differentiation status were detected. Disease-free and overall survival were significantly poorer for patients with positive MMP-9 staining than for those with MMP-9-negative tumors.

Conclusions: Our findings emphasize the important role of MMP-9 in the invasion and metastasis process in human colorectal cancer. It could also serve as a novel prognostic marker that is independent of, and additive to, the tumor-node-metastasis (TNM) staging system.

Citing Articles

Molecular and phenotypic distinctions of macrophages in tolerant and susceptible to hypoxia rats.

Dzhalilova D, Kosyreva A, Lokhonina A, Tsvetkov I, Vishnyakova P, Makarova O PeerJ. 2023; 11:e16052.

PMID: 37842051 PMC: 10573310. DOI: 10.7717/peerj.16052.


Construction of a fecal immune-related protein-based biomarker panel for colorectal cancer diagnosis: a multicenter study.

Zhang H, Zuo L, Li J, Geng Z, Ge S, Song X Front Immunol. 2023; 14:1126217.

PMID: 37313408 PMC: 10258350. DOI: 10.3389/fimmu.2023.1126217.


Single-cell sequencing reveals the immune microenvironment landscape related to anti-PD-1 resistance in metastatic colorectal cancer with high microsatellite instability.

Wu T, Zhang X, Liu X, Cai X, Shen T, Pan D BMC Med. 2023; 21(1):161.

PMID: 37106440 PMC: 10142806. DOI: 10.1186/s12916-023-02866-y.


Characterization of Active MMP9 in Chronic Inflammatory Diseases Using a Novel Anti-MMP9 Antibody.

Velasquez M, OSullivan C, Brockett R, Mikels-Vigdal A, Mikaelian I, Smith V Antibodies (Basel). 2023; 12(1).

PMID: 36810514 PMC: 9944116. DOI: 10.3390/antib12010009.


Impact of Patient Characteristics on the Outcomes of Patients with Gastrointestinal Cancers Treated with Immune Checkpoint Inhibitors.

Ohm H, Abdel-Rahman O Curr Oncol. 2023; 30(1):786-802.

PMID: 36661709 PMC: 9858132. DOI: 10.3390/curroncol30010060.